MCID: PPL007
MIFTS: 41

Papillary Serous Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Serous Adenocarcinoma

MalaCards integrated aliases for Papillary Serous Adenocarcinoma:

Name: Papillary Serous Adenocarcinoma 12 15
Serous Surface Papillary Carcinoma 12 71
Micropapillary Serous Carcinoma 12 17
Papillary Serous Cystadenocarcinoma 71
Papillary Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2632
SNOMED-CT 67 15674004 90282004
UMLS 71 C0334359 C0334361

Summaries for Papillary Serous Adenocarcinoma

Disease Ontology : 12 A papillary adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures with psammoma bodies.

MalaCards based summary : Papillary Serous Adenocarcinoma, also known as serous surface papillary carcinoma, is related to uterine corpus serous adenocarcinoma and endometriosis of ovary. An important gene associated with Papillary Serous Adenocarcinoma is KRT7 (Keratin 7), and among its related pathways/superpathways are Gastric cancer and MicroRNAs in cancer. The drugs Epirubicin and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and thyroid, and related phenotypes are endocrine/exocrine gland and neoplasm

Related Diseases for Papillary Serous Adenocarcinoma

Diseases related to Papillary Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 448)
# Related Disease Score Top Affiliating Genes
1 uterine corpus serous adenocarcinoma 31.7 WT1 TP53 KRAS BRCA1
2 endometriosis of ovary 30.4 PGR MIR30E MIR141
3 fallopian tube adenocarcinoma 30.4 CALB2 BRCA1
4 large cell neuroendocrine carcinoma 30.3 PGR NKX2-1 KRT7 KRT20
5 bilateral breast cancer 30.2 PGR BRCA2 BRCA1
6 intestinal obstruction 30.1 KRT7 KRT20 CEACAM5
7 ovarian brenner tumor 30.1 WT1 KRT7 KRT20
8 endometrial adenocarcinoma 30.1 TP53 PGR KRT7 KRAS
9 endometrial hyperplasia 30.1 TP53 PGR KRAS
10 angiomyolipoma 30.0 PGR PAX8 KRT7
11 papillary carcinoma 30.0 PGR PAX8 NKX2-1 KRT7 KRT20 CALB2
12 neuroendocrine carcinoma 30.0 NKX2-1 KRT7 KRT20 CEACAM5
13 primary peritoneal carcinoma 29.9 TP53 PGR BRCA2 BRCA1
14 myoma 29.9 PGR KRAS CEACAM5
15 cervical adenocarcinoma 29.9 TP53 KRT7 KRT20 CEACAM5 CALB2
16 in situ carcinoma 29.7 TP53 PGR MIR30A BRCA2 BRCA1
17 polycystic liver disease 1 with or without kidney cysts 29.7 KRT7 KRT20 CEACAM5 CALB2
18 cystadenocarcinoma 29.7 TP53 PGR MIR30A KRT7 CEACAM5
19 adenocarcinoma 29.7 TP53 NKX2-1 KRT7 KRT20 KRAS CEACAM5
20 cervix carcinoma 29.6 TP53 MIR625 MIR141 CEACAM5
21 clear cell adenocarcinoma 29.5 TP53 PGR PAX8 KRT7 KRT20
22 hereditary breast ovarian cancer syndrome 29.5 TP53 KRAS BRCA2 BRCA1
23 malignant epithelial mesothelioma 29.4 WT1 CEACAM5 CALB2
24 adenofibroma 29.2 WT1 TP53 KRT7 CALB2
25 adenosquamous carcinoma 29.2 TP53 PGR NKX2-1 KRT7 KRAS CEACAM5
26 ovarian disease 29.2 TP53 PGR KRAS BRCA2 BRCA1
27 endocervical carcinoma 29.2 TP53 PGR PAX8 KRT7 CEACAM5
28 endocervical adenocarcinoma 29.0 TP53 PGR PAX8 KRT7 KRT20 CEACAM5
29 mesothelioma, malignant 28.9 WT1 NKX2-1 KRT7 KRT20 CEACAM5 CALB2
30 small cell carcinoma 28.9 WT1 TP53 NKX2-1 KRT7 KRT20 KRAS
31 serous cystadenocarcinoma 28.5 WT1 TP53 PGR PAX8 MIR30A KRAS
32 benign mesothelioma 28.4 WT1 PAX8 KRT7 CEACAM5 CALB2
33 fallopian tube carcinoma 28.3 WT1 TP53 PGR PAX8 BRCA2 BRCA1
34 ovarian serous carcinoma 28.1 WT1 TP53 PAX8 MIR141 KRAS CALB2
35 carcinosarcoma 28.1 WT1 TP53 PGR PAX8 KRT7 KRAS
36 pancreatic cancer 27.9 TP53 MIR30A MIR141 KRT7 KRT20 KRAS
37 papillary adenocarcinoma 27.5 TP53 PGR NKX2-1 MIR30E MIR30A MIR141
38 wilms tumor 1 27.2 WT1 TP53 PGR PAX8 KRT7 KRAS
39 ovarian cystadenocarcinoma 27.1 TP53 PAX8 MIR505 MIR30A KRAS CEACAM5
40 peritoneum cancer 27.1 WT1 TP53 PAX8 KRT7 CEACAM5 CALB2
41 endometrial cancer 26.5 WT1 TP53 PGR PAX8 NKX2-1 KRT7
42 breast cancer 26.3 WT1 TP53 PGR NKX2-1 MIR30E MIR30A
43 ovary adenocarcinoma 25.7 WT1 TP53 PGR PAX8 MIR30A KRT7
44 ovarian cancer 25.5 WT1 TP53 PGR PAX8 MIR30E MIR30A
45 ovary papillary carcinoma 11.6
46 bartholin's gland adenoid cystic carcinoma 10.6 PGR KRT7
47 pancreatic serous cystadenocarcinoma 10.6 KRT7 KRT20
48 intrahepatic bile duct adenoma 10.6 KRT7 KRT20
49 gastric signet ring cell adenocarcinoma 10.6 KRT7 KRT20
50 ovarian large-cell neuroendocrine carcinoma 10.6 KRT7 KRT20

Graphical network of the top 20 diseases related to Papillary Serous Adenocarcinoma:



Diseases related to Papillary Serous Adenocarcinoma

Symptoms & Phenotypes for Papillary Serous Adenocarcinoma

MGI Mouse Phenotypes related to Papillary Serous Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.97 BRCA1 BRCA2 KRAS NKX2-1 PAX8 PGR
2 neoplasm MP:0002006 9.8 BRCA1 BRCA2 KRAS NKX2-1 PGR TP53
3 no phenotypic analysis MP:0003012 9.76 CDKL2 KRAS NKX2-1 PAX8 PGR STK36
4 normal MP:0002873 9.61 BRCA1 BRCA2 CALB2 KRAS NKX2-1 PAX8
5 renal/urinary system MP:0005367 9.23 ANXA4 BRCA1 KRAS KRT7 PAX8 STK36

Drugs & Therapeutics for Papillary Serous Adenocarcinoma

Drugs for Papillary Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
3
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
4
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
5
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
6
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
7
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
8
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
9
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
10
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
11
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
12
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
13
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
14
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
15
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
16
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
17 Estrogens Phase 2, Phase 3
18 Aromatase Inhibitors Phase 2, Phase 3
19 Anti-Infective Agents Phase 2, Phase 3
20 Hormone Antagonists Phase 2, Phase 3
21 Antibiotics, Antitubercular Phase 2, Phase 3
22 Anti-Bacterial Agents Phase 2, Phase 3
23 Antifungal Agents Phase 2, Phase 3
24 Immunosuppressive Agents Phase 2, Phase 3
25 Steroid Synthesis Inhibitors Phase 2, Phase 3
26 Estrogen Receptor Antagonists Phase 2, Phase 3
27 Estrogen Antagonists Phase 2, Phase 3
28 Immunologic Factors Phase 2, Phase 3
29 Hormones Phase 2, Phase 3
30 Albumin-Bound Paclitaxel Phase 3
31 Antimitotic Agents Phase 3
32 Protein Kinase Inhibitors Phase 2, Phase 3
33 topoisomerase I inhibitors Phase 2, Phase 3
34 Citrate Phase 2, Phase 3
35 Selective Estrogen Receptor Modulators Phase 2, Phase 3
36 Free Radical Scavengers Phase 2, Phase 3
37 Antioxidants Phase 2, Phase 3
38 Anticoagulants Phase 2, Phase 3
39 Topoisomerase Inhibitors Phase 2, Phase 3
40 Chelating Agents Phase 2, Phase 3
41 Protective Agents Phase 2, Phase 3
42 Antineoplastic Agents, Hormonal Phase 2, Phase 3
43
Liposomal doxorubicin Phase 2, Phase 3 31703
44 Estrogen Receptor Modulators Phase 2, Phase 3
45 Calcium, Dietary Phase 2, Phase 3
46
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
48
Cimetidine Approved, Investigational Phase 2 51481-61-9 2756
49
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
50
Histamine Approved, Investigational Phase 2 51-45-6 774

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
2 WHOLE ABDOMINAL RADIOTHERAPY VERSUS CIRCADIAN-TIMED COMBINATION DOXORUBICIN-CISPLATIN CHEMOTHERAPY IN ADVANCED ENDOMETRIAL CARCINOMA -- PHASE III Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
3 A Randomized Trial of Adjuvant Treatment With Radiation Plus Chemotherapy Versus Radiation Alone in High Risk Endometrial Carcinoma Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
4 A Randomised Trial of Lymphadenectomy and of Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer Completed NCT00003749 Phase 3
5 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
6 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen;Tamoxifen Citrate;Topotecan;Topotecan Hydrochloride;Trametinib;Trametinib Dimethyl Sulfoxide
7 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
8 A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) Active, not recruiting NCT01672892 Phase 3
9 A Phase II Study of Docetaxel and Carboplatin for Suboptimally Debulked Stage III or Stage IV Ovarian and Fallopian Tube Carcinoma Unknown status NCT00003560 Phase 2 carboplatin;docetaxel
10 Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00022620 Phase 2 paclitaxel
11 A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
12 A Phase II Study: Paclitaxel and Pelvic Radiation for Stage I-IIIA Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
13 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
14 Randomized Trial Of Adriamycin (A) Cisplatin (P) Chemotherapy Versus Paclitaxel (T) Adriamycin (A) And Cisplatin (P) In Patients With Metastatic/Relapsed Or Locally Advanced Inoperable Endometrial Cancer Completed NCT00052312 Phase 2 cisplatin;doxorubicin hydrochloride;paclitaxel
15 Prospective, Non-randomised Phase 2 Clinical Trial of Carboplatin Plus Paclitaxel With Sequential Radical Pelvic Radiotherapy for Uterine Serous Papillary Cancer Completed NCT00147680 Phase 2 Paclitaxel, Carboplatin
16 A Cancer Research UK Phase II Proof of Principle Trial of the Activity of the PARP-1 Inhibitor, AG-014699, in Known Carriers of a BRCA 1 or BRCA 2 Mutation With Locally Advanced or Metastatic Breast or Advanced Ovarian Cancer Completed NCT00664781 Phase 2 rucaparib (CO-338; formally AG-014699 or PF-01367338)
17 Phase II Trial- Weekly Taxotere and Topotecan for Recurrent Ovarian, Primary Peritoneal, Endometrial and Uterine Cancers Completed NCT00231855 Phase 2 Topotecan and Taxotere
18 A Pilot Phase II Trial of Celecoxib in Patients With Grade 2 or 3 Endometrioid-type, Clear Cell, and Papillary Serous Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
19 Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers Completed NCT01198184 Phase 1 temsirolimus;gamma-secretase/Notch signalling pathway inhibitor RO4929097
20 A Phase I Study of Stereotactic Body Radiation Therapy for Patients With Limited Locoregional Recurrences of Ovarian and Uterine Serous Carcinoma Recruiting NCT03325634 Phase 1
21 The Use and Safety of Metformin, Carboplatin and Paclitaxel in Non-Diabetic Patients With Recurrent, Platinum Sensitive Ovarian Cancer and the Feasibility of Using a Core Biopsy for RNA-Seq Withdrawn NCT02050009 Phase 1 metformin hydrochloride;carboplatin;paclitaxel
22 Role of Sex Hormone and Insulin/IGF Axes in Endometrial Cancer Recurrence Unknown status NCT01150682
23 Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine Completed NCT02774395
24 Sub-type Specific Genomic Mutations in Serous Borderline Ovarian Tumors Active, not recruiting NCT03883542
25 The Role of Synuclein-gamma (SNCG) in the Carcinogenesis of Uterine Papillary Serous Carcinoma Not yet recruiting NCT01344837
26 Racial Disparity in Prevalence and Survival Rates in Endometrial Cancer Terminated NCT00375804

Search NIH Clinical Center for Papillary Serous Adenocarcinoma

Genetic Tests for Papillary Serous Adenocarcinoma

Anatomical Context for Papillary Serous Adenocarcinoma

MalaCards organs/tissues related to Papillary Serous Adenocarcinoma:

40
Breast, Ovary, Thyroid, Colon, Lung, Cervix, Thymus

Publications for Papillary Serous Adenocarcinoma

Articles related to Papillary Serous Adenocarcinoma:

(show top 50) (show all 137)
# Title Authors PMID Year
1
Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells. 61
31029905 2019
2
Brain Metastasis in Papillary Serous Adenocarcinoma of the Endometrium. 61
30991420 2019
3
Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy. 61
30694943 2019
4
Ovarian cancer unmasked by technetium-99m bone scintigraphy and single-photon emission computed tomography-computed tomography. 61
30774548 2019
5
[A Case of Splenic Metastasis from Serous Surface Papillary Carcinoma of the Peritoneum Treated by Laparoscopic Splenectomy]. 61
29650839 2018
6
Primary Adenocarcinoma of the Fallopian Tube: A Rare Entity. 61
29207787 2017
7
Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity. 61
28551646 2017
8
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review. 61
28399919 2017
9
[Clinical-based study of ovarian cancer patients with and without BRCA1/2 genes mutation: clinical features and pedigree analysis]. 61
28190311 2017
10
Filarial worm residing in ovarian papillary serous adenocarcinoma-A rare case report. 61
27444355 2016
11
FDG PET/CT Imaging of Calcified Sister Mary Joseph Nodule. 61
27405031 2016
12
Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. 61
27426853 2016
13
In vitro effect of IL-17D on human ovarian carcinoma cells and inherent immunity. 61
27655504 2016
14
Hydrosalpinx as a Rare Presentation of Synchronous Ovarian and Endometrial Carcinoma - A Case Report. 61
27630913 2016
15
Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy. 61
26825824 2016
16
Bilateral primary fallopian tube papillary serous carcinoma in postmenopausal woman: Report of two cases. 61
27134480 2016
17
Colonic Metastasis Presenting as an Intraluminal Fungating Mass 8 Years After Surgery for Ovarian Cancer. 61
26576399 2015
18
Reduced expression and growth inhibitory activity of the aging suppressor klotho in epithelial ovarian cancer. 61
25827069 2015
19
Epothilone B induces human ovarian cancer OV-90 cell apoptosis via external pathway. 61
25721485 2015
20
Abdominal aortic resection and Y-graft placement to achieve complete cytoreduction in stage IIIc ovarian carcinoma. 61
24413236 2014
21
[Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases]. 61
24273914 2013
22
Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. 61
23290009 2013
23
Multiple brain metastases in a patient with uterine papillary serous adenocarcinoma: Treatment options for this rarely seen metastatic brain tumor. 61
24032086 2013
24
Papillary serous carcinoma of the cervix mixed with squamous cells: A report of the first case. 61
24371711 2013
25
Malignant mixed mullerian tumor of endometrium coexisting with bilateral papillary serous adenocarcinoma of fallopian tube: a rare case report. 61
24293882 2012
26
High-grade primary peritoneal serous papillary carcinoma with a wide differential diagnosis: a diagnostic challenge. 61
23547430 2012
27
Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53 (+/-) transgenic mice. 61
23164239 2012
28
Papillary-serous adenocarcinoma of the uterine cervix during tamoxifen therapy after bilateral breast cancer. 61
23155282 2012
29
[Papillary serous adenocarcinoma of the endometrium and ovary]. 61
22987388 2012
30
F-18 fluoride uptake in calcified extraosseous metastases from ovarian papillary serous adenocarcinoma. 61
22157054 2012
31
Endometrioid adenocarcinoma with high-grade transformation with serous and choriocarcinomatous differentiation - a case report. 61
22211141 2012
32
Multiple gastric metastases from ovarian carcinoma diagnosed by endoscopic ultrasound with fine needle aspiration. 61
22811942 2012
33
Pancreatic metastasis of high-grade papillary serous ovarian carcinoma mimicking primary pancreas cancer: a case report. 61
22829843 2012
34
Gastrointestinal stromal tumor with synchronous isolated parenchymal splenic metastasis of ovarian cancer. 61
22340419 2011
35
Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. 61
22017790 2011
36
A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival. 61
21720254 2011
37
[Epidemiological profile of ovarian cancer]. 61
21966857 2011
38
Endometrial cancer, types, prognosis, female hormones and antihormones. 61
21426234 2011
39
[A case of serous surface papillary carcinoma of the peritoneum metastatic to the brain]. 61
21628741 2011
40
Papillary serous adenocarcinoma of the uterine cervix: a case report. 61
21614930 2011
41
Conservative surgery in cervical cancer: report of two radical abdominal trachelectomies and literature review. 61
22335046 2011
42
Consequences of abdominal adenocarcinoma in post-menopausal woman in relation to surgical and non-surgical management. 61
21863621 2011
43
Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. 61
21041624 2010
44
Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. 61
19766980 2010
45
Acute gastric outlet obstruction secondary to papillary serous adenocarcinoma of the endometrium with peritoneal psammomatous implants: a case report. 61
19132421 2010
46
Cisplatinum and docetaxel for ovarian cancer in pregnancy. 61
19242705 2009
47
F-18 FDG PET-CT findings in a case of normal-sized ovarian cancer syndrome. 61
19893409 2009
48
99mTc-MDP and 18F-FDG uptake in calcified metastatic lesions from ovarian papillary serous adenocarcinoma. 61
19936349 2009
49
Successful Treatment of Primary Vaginal Papillary Serous Adenocarcinoma Using Chemoradiation Followed by Brachytherapy. 61
20740170 2009
50
Video-assisted thoracoscopic surgery for recurrent ovarian cancer with a metastatic mediastinal mass. 61
19420974 2009

Variations for Papillary Serous Adenocarcinoma

Expression for Papillary Serous Adenocarcinoma

Search GEO for disease gene expression data for Papillary Serous Adenocarcinoma.

Pathways for Papillary Serous Adenocarcinoma

Pathways related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.22 TP53 PGR KRAS BRCA2 BRCA1
2 11.66 TP53 MIR625 MIR30E MIR30A MIR141 KRAS
3 11.44 TP53 KRAS BRCA2 BRCA1
4
Show member pathways
11.35 TP53 BRCA2 BRCA1

GO Terms for Papillary Serous Adenocarcinoma

Biological processes related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 WT1 TP53 MIR30A CEACAM5 ANXA4
2 gene silencing by miRNA GO:0035195 9.76 MIR505 MIR30E MIR30A MIR141
3 positive regulation of transcription, DNA-templated GO:0045893 9.73 WT1 TP53 PAX8 NKX2-1 BRCA2 BRCA1
4 double-strand break repair GO:0006302 9.61 TP53 BRCA2 BRCA1
5 positive regulation of gene expression GO:0010628 9.43 WT1 TP53 NKX2-1 MIR30A KRAS BRCA1
6 cellular response to gonadotropin stimulus GO:0071371 9.4 WT1 PAX8
7 metanephric S-shaped body morphogenesis GO:0072284 9.37 WT1 PAX8
8 metanephric epithelium development GO:0072207 9.32 WT1 PAX8
9 chordate embryonic development GO:0043009 9.16 BRCA2 BRCA1
10 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 TP53 BRCA2 BRCA1

Molecular functions related to Papillary Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.26 MIR505 MIR30E MIR30A MIR141
2 transcription regulatory region DNA binding GO:0044212 9.02 WT1 TP53 PAX8 NKX2-1 BRCA1

Sources for Papillary Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....